Eli Lilly’s Alzheimer’s Drug And Italfarmaco’s Duchenne Treatment Due For Oral Explanations At EMA

The sponsors of nine new medicines that are in the final stages of their review cycle in the EU were due or possibly due to appear before the European Medicines Agency to address outstanding concerns the agency has regarding the marketing applications of their products.